Anti-adenylate kinase 5 encephalitis: Clinical characteristics, diagnosis, and management of this rare entity

Abbatemarco, 2021, Antibody-mediated autoimmune encephalitis: a practical approach, Cleve. Clin. J. Med., 88, 459, 10.3949/ccjm.88a.20122 Zhang, 2022, Editorial: antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management, Front. Neurol., 13 Abboud, 2021, Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management, J. Neurol. Neurosurg. Psychiatry, 92, 757, 10.1136/jnnp-2020-325300 Graus, 2016, A clinical approach to diagnosis of autoimmune encephalitis, Lancet Neurol., 15, 391, 10.1016/S1474-4422(15)00401-9 Bien, 2000, Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy, Neurology, 55, 1823, 10.1212/WNL.55.12.1823 Watanabe, 2003, Steroid-responsive limbic encephalitis, Intern. Med., 42, 428, 10.2169/internalmedicine.42.428 Tüzün, 2007, Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis, J. Neuroimmunol., 186, 177, 10.1016/j.jneuroim.2007.03.015 van Sonderen, 2016, From VGKC to LGI1 and Caspr2 encephalitis: the evolution of a disease entity over time, Autoimmun. Rev., 15, 970, 10.1016/j.autrev.2016.07.018 Muñiz-Castrillo, 2021, Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis, Brain, 144, 2709, 10.1093/brain/awab153 Li, 2022, Kelch-like protein 11 antibody-associated paraneoplastic neurological syndrome: a state-of-the-art review, Clin. Immunol., 241, 10.1016/j.clim.2022.109074 Do, 2017, Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies, Neurology, 88, 514, 10.1212/WNL.0000000000003586 Bien, 2019, Identification of adenylate kinase 5 antibodies during routine diagnostics in a tissue-based assay: three new cases and a review of the literature, J. Neuroimmunol., 334, 10.1016/j.jneuroim.2019.576975 Vicino, 2021, Anti-adenylate kinase 5 encephalitis with histologic evidence of CNS vasculitis, Neurol. Neuroimmunol. Neuroinflamm., 8, 10.1212/NXI.0000000000001010 Guillaume, 2022, Anti-AK5 encephalitis: subacute anterograde amnesia is not the only clinical presentation, Acta Neurol. Belg., 299 McKeon-Makki, 2022, Adenylate kinase 5 (AK5) autoimmune encephalitis: clinical presentations and outcomes in three new patients, J. Neuroimmunol., 367, 10.1016/j.jneuroim.2022.577861 Muñiz-Castrillo, 2020, Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies, J. Neurol., 267, 1906, 10.1007/s00415-020-09782-8 Ahn, 2021, Identification of novel DNA hypermethylation of the adenylate kinase 5 promoter in colorectal adenocarcinoma, Sci. Rep., 11, 10.1038/s41598-021-92147-6 Ng, 2015, Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis, J. Neuroimmunol., 287, 31, 10.1016/j.jneuroim.2015.08.009 Bien, 2012, Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis, Brain, 135, 1622, 10.1093/brain/aws082 Dalmau, 2004, Clinical analysis of anti-Ma2-associated encephalitis, Brain, 127, 1831, 10.1093/brain/awh203 Rosenblum, 1993, Paraneoplasia and autoimmunologic injury of the nervous system: the anti-Hu syndrome, Brain Pathol., 3, 199, 10.1111/j.1750-3639.1993.tb00747.x Ariño, 2016, Anti-LGI1-associated cognitive impairment: presentation and long-term outcome, Neurology, 87, 759, 10.1212/WNL.0000000000003009 Joubert, 2016, Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures, JAMA Neurol., 73, 1115, 10.1001/jamaneurol.2016.1585 Seery, 2022, Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis, Autoimmun. Rev., 21 Tsiortou, 2021, GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions, Ther. Adv. Neurol. Disord., 14, 10.1177/17562864211003486 Guillaume, 2023, Anti-AK5 encephalitis: subacute anterograde amnesia is not the only clinical presentation, Acta Neurol. Belg., 123, 299, 10.1007/s13760-021-01853-5 Scheltens, 2021, Alzheimer's disease, Lancet, 397, 1577, 10.1016/S0140-6736(20)32205-4 Hermann, 2021, Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease, Lancet Neurol., 20, 235, 10.1016/S1474-4422(20)30477-4 Abboud, 2021, Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management, J. Neurol. Neurosurg. Psychiatry, 92, 897, 10.1136/jnnp-2020-325302 Bien, 2022, Limbic encephalitis, handb, Clin. Neurol., 187, 467 van Sonderen, 2017, The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis, Nat. Rev. Neurol., 13, 290, 10.1038/nrneurol.2017.43 Ghimire, 2020, Anti-LGI1, anti-GABABR, and Anti-CASPR2 encephalitides in Asia: a systematic review, Brain Behav., 10, 10.1002/brb3.1793 van Sonderen, 2016, The clinical spectrum of Caspr2 antibody-associated disease, Neurology, 87, 521, 10.1212/WNL.0000000000002917 Zhang, 2021, Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor encephalitis: a review, Front. Immunol., 12 Dalmau, 2019, An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models, Lancet Neurol., 18, 1045, 10.1016/S1474-4422(19)30244-3 Dubey, 2020, Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic kelch-like protein-11 encephalitis, JAMA Neurol., 77, 1420, 10.1001/jamaneurol.2020.2231 Mandel-Brehm, 2019, Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis, N. Engl. J. Med., 381, 47, 10.1056/NEJMoa1816721 Vogrig, 2021, Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis, Brain Commun, 3, 10.1093/braincomms/fcab185 Mrabet, 2015, Anti-Ma2-encephalitis in a 2 year-old child: a newly diagnosed case and literature review, Eur. J. Paediatr. Neurol., 19, 737, 10.1016/j.ejpn.2015.06.005 Graus, 2019, Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors, Nat. Rev. Clin. Oncol., 16, 535, 10.1038/s41571-019-0194-4 Budhram, 2022, Clinical sensitivity, specificity, and predictive value of neural antibody testing for autoimmune encephalitis, J. Appl. Lab. Med., 7, 350, 10.1093/jalm/jfab127 Schwenkenbecher, 2016, Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis, BMC Neurol., 16, 136, 10.1186/s12883-016-0657-5 Li, 2016, Anti-Hu antibodies activate enteric and sensory neurons, Sci. Rep., 6 Spatola, 2018, Encephalitis with mGluR5 antibodies: symptoms and antibody effects, Neurology, 90, e1964, 10.1212/WNL.0000000000005614 Graus, 2020, GAD antibodies in neurological disorders - insights and challenges, Nat. Rev. Neurol., 16, 353, 10.1038/s41582-020-0359-x Ariño, 2015, Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies, JAMA Neurol., 72, 874, 10.1001/jamaneurol.2015.0749 Gresa-Arribas, 2015, Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity, PLoS One, 10, 10.1371/journal.pone.0121364 Dade, 2020, Neurological syndromes associated with anti-GAD antibodies, Int. J. Mol. Sci., 21, 3701, 10.3390/ijms21103701